H 103

Drug Profile

H 103

Alternative Names: H-103; Oncolytic recombinant adenovirus injection - Shanghai Sunway Biotech

Latest Information Update: 08 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Sunway Biotech
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Gene therapies; Oncolytic viruses
  • Mechanism of Action P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 08 Oct 2015 Phase-I clinical trials in Cancer in China (Intratumoural) before October 2015
  • 08 Oct 2015 Shanghai Sunway Biotech completes a phase I trial in Cancer in China (Shanghai Sunway Pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top